Albarrán Víctor, Villamayor María Luisa, Pozas Javier, Chamorro Jesús, Rosero Diana Isabel, San Román María, Guerrero Patricia, Pérez de Aguado Patricia, Calvo Juan Carlos, García de Quevedo Coral, González Carlos, Vaz María Ángeles
Medical Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, Spain.
Cancers (Basel). 2023 Apr 13;15(8):2287. doi: 10.3390/cancers15082287.
There is substantial heterogeneity between different subtypes of sarcoma regarding their biological behavior and microenvironment, which impacts their responsiveness to immunotherapy. Alveolar soft-part sarcoma, synovial sarcoma and undifferentiated pleomorphic sarcoma show higher immunogenicity and better responses to checkpoint inhibitors. Combination strategies adding immunotherapy to chemotherapy and/or tyrosine-kinase inhibitors globally seem superior to single-agent schemes. Therapeutic vaccines and different forms of adoptive cell therapy, mainly engineered TCRs, CAR-T cells and TIL therapy, are emerging as new forms of immunotherapy for advanced solid tumors. Tumor lymphocytic infiltration and other prognostic and predictive biomarkers are under research.
肉瘤的不同亚型在生物学行为和微环境方面存在显著异质性，这影响了它们对免疫治疗的反应性。肺泡软组织肉瘤、滑膜肉瘤和未分化多形性肉瘤显示出更高的免疫原性，对检查点抑制剂的反应更好。在全球范围内，将免疫治疗与化疗和/或酪氨酸激酶抑制剂联合使用的策略似乎优于单药治疗方案。治疗性疫苗和不同形式的过继性细胞疗法，主要是工程化TCR、CAR-T细胞和肿瘤浸润淋巴细胞疗法，正在成为晚期实体瘤免疫治疗的新形式。肿瘤淋巴细胞浸润以及其他预后和预测性生物标志物正在研究中。
